3089845-68-8
3089845-68-8
Chemical Structure
GZNL-P36
- CAS No.: 3089845-68-8
- Formula:C29H30N4O2
- Molecular Weight:466.57
InChIKey: BSWURDVCCQYDFG-UHFFFAOYSA-N
SMILES: CN1C2=CC=C(C3(CC3)NC(C4=CC(N5CC(C6)N(C)C6C5)=CC=C4C)=O)C7=C2C(C1=O)=CC=C7
Biological Activity: GZNL-P36 is an orally active inhibitor for SARS-CoV-2 papain-like protease (PLpro), with an IC50 of 6.45 nM. GZNL-P36 inhibits SARS-CoV and its variants with EC50 range from 58.2 nM to 2.66 μM. GZNL-P36 exhibits a peak plasma concentration Cmax of 549 ng/mL, a half-life T1/2 of 1.45 h and a bioavailability of 74.7% in CD-1 mouse. GZNL-P36 exhibits antiviral activity in SARS-CoV-2 XXB.1 infection in mouse[1].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
GZNL-P36 | 98.97% | GZNL-P36 is an orally active inhibitor for SARS-CoV-2 papain-like protease (PLpro), with an IC50 of 6.45 nM. GZNL-P36 inhibits SARS-CoV and its variants with EC50 range from 58.2 nM to 2.66 μM. GZNL-P36 exhibits a peak plasma concentration Cmax of 549 ng/mL, a half-life T1/2 of 1.45 h and a bioavailability of 74.7% in CD-1 mouse. GZNL-P36 exhibits antiviral activity in SARS-CoV-2 XXB.1 infection in mouse. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
